Phase 2 Pancreatic Cancer Trial, Recruiting NCT07066995 Sponsor: Essen Biotech Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 2 Pancreatic Cancer Trial, Recruiting

NCT07066995
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Doctors expect you to live for at least 3 more months.
  • You have been diagnosed with pancreatic cancer (a specific type called adenocarcinoma) that has spread or cannot be removed by surgery, and you have already tried standard chemotherapy treatments (such as gemcitabine/nab-paclitaxel or FOLFIRINOX), could not tolerate them, or your cancer has continued to grow despite treatment.
  • You are generally able to care for yourself and are up and about for most of the day, even if you cannot do heavy physical activity (confirm with trial site what this means for your situation).
  • Your kidney function blood test results are within an acceptable range.
  • Your heart trace (ECG) does not show any worrying abnormalities.
  • Your blood oxygen level is above 91% without needing extra oxygen.
  • Your liver function blood test results are within an acceptable range (slightly higher limits may be allowed in certain situations, such as a specific liver condition called Gilbert syndrome — confirm with trial site).
  • You do not have any serious mental health conditions.
  • You understand what the trial involves and are willing to sign a consent form.

Who may not be able to join:

  • You currently have active Hepatitis B, Hepatitis C, HIV, or syphilis infections.
  • You have a serious heart condition, such as unstable chest pain, a recent heart attack, recent heart bypass or stent surgery (within the last 6 months), significant heart failure, or a severe irregular heartbeat.
  • You have an unstable serious illness affecting the liver, kidneys, or metabolism that requires ongoing medication.
  • You have an active or uncontrolled infection (other than a mild urinary or common cold-type infection) that has needed treatment in the 7 days before receiving the trial treatment.
  • You are pregnant, breastfeeding, or plan to become pregnant within 2 years of receiving the treatment — this also applies to male participants whose partners plan to become pregnant within 2 years.
  • You have previously received a type of treatment called CAR-T therapy or any other gene-modified cell therapy.
  • You have taken part in another clinical trial within the last month.
  • There are signs that your cancer has spread to your brain or spinal cord.
  • You have depression or thoughts of suicide or self-harm.
  • The trial doctors have any other concerns that they believe make it unsuitable for you to join (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +12077706670

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Essen Biotech
Registry
ClinicalTrials.gov
Start date
29 April 2025
Est. completion
10 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence and severity of dose-limiting toxicities (DLTs) following chemotherapy preparative regimen and infusion of CD19/BCMA chimeric antigen receptor (CAR) T cells

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov